270 related articles for article (PubMed ID: 35022306)
1. Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease.
Whittington MD; Campbell JD; Rind D; Fluetsch N; Lin GA; Pearson SD
Neurology; 2022 Mar; 98(9):e968-e977. PubMed ID: 35022306
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price.
Sinha P; Barocas JA
Alzheimers Dement (N Y); 2022; 8(1):e12256. PubMed ID: 35282659
[TBL] [Abstract][Full Text] [Related]
4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.
Villacorta R; Hay JW; Messali A
Pharmacoeconomics; 2013 Sep; 31(9):823-39. PubMed ID: 23975739
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.
Sehested TSG; Bjerre J; Ku S; Chang A; Jahansouz A; Owens DK; Hlatky MA; Goldhaber-Fiebert JD
JAMA Cardiol; 2019 Feb; 4(2):128-135. PubMed ID: 30649147
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
9. Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
Yigit V; Kalender S; Cetinturk I
Cost Eff Resour Alloc; 2023 Aug; 21(1):51. PubMed ID: 37559042
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
Lien PW; Joshi M; Tice JA; Agboola F; Nikitin D; Withanawasam V; Jatoi S; Touchette DR
J Manag Care Spec Pharm; 2024 Jun; 30(6):517-527. PubMed ID: 38824625
[TBL] [Abstract][Full Text] [Related]
12. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors.
Ito K; Chapman R; Pearson SD; Tafazzoli A; Yaffe K; Gurwitz JH
JAMA Netw Open; 2021 Oct; 4(10):e2129392. PubMed ID: 34677596
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease.
Boustani M; Doty EG; Garrison LP; Smolen LJ; Belger M; Klein TM; Murphy DR; Burge R; Wall JK; Johnston JA
Clin Ther; 2022 Nov; 44(11):1449-1462. PubMed ID: 36210219
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
[TBL] [Abstract][Full Text] [Related]
16. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
17. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
[TBL] [Abstract][Full Text] [Related]
18. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.
Lipton RB; Brennan A; Palmer S; Hatswell AJ; Porter JK; Sapra S; Villa G; Shah N; Tepper S; Dodick D
J Med Econ; 2018 Jul; 21(7):666-675. PubMed ID: 29571276
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
